WIN 18,446 is a bis-(dichloroacetyl)-diamine which inhibits aldehyde dehydrogenase 1a2, (IC50 = 300 nM), a testes-specific isoform of the enzyme involved in vitamin A metabolism. In this way, WIN 18,446 suppresses the expression of several genes that are regulated by retinoic acid and are necessary for spermatogenesis. As a result, WIN 18,446 may cause infertility in males.
WIN 18,446 is a bis-(dichloroacetyl)-diamine which inhibits aldehyde dehydrogenase 1a2, (IC50 = 300 nM), a testes-specific isoform of the enzyme involved in vitamin A metabolism. In this way, WIN 18,446 suppresses the expression of several genes that are regulated by retinoic acid and are necessary for spermatogenesis. As a result, WIN 18,446 may cause infertility in males.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.